title: Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss.
abstract: OBJECTIVE
  To compare the efficacy of rectally administered misoprostol with intravenous oxytocin infusion in preventing uterine atony and blood loss during cesarean delivery.
  
  
  METHODS
  In this prospective, randomized, double-blind trial, 200 women undergoing cesarean delivery who did not have risk factors for postpartum hemorrhage were randomly allocated to receive either 800 microg of rectal misoprostol at the time of peritoneal incision or an intravenous infusion of oxytocin after delivery of the neonate. Primary outcome measures were estimated amount of intraoperative and postoperative (8 hours) blood loss and changes in hemoglobin levels 24 hours after delivery.
  
  
  RESULTS
  A total of 96 and 94 women were analyzed in the misoprostol and oxytocin groups, respectively. Intraoperative and postoperative blood loss was significantly lower in the misoprostol group than in the oxytocin group (503 vs 592 mL, P=0.003 and 74 vs 114 mL, P=0.045, respectively). The incidence of shivering was higher in the misoprostol group (8.3% vs 1.1%, P=0.018; RR 7.83; 95% confidence interval, 0.99-61.42).
  
  
  CONCLUSIONS
  Rectal misoprostol appears to be an effective alternative to intravenous oxytocin in preventing blood loss for routine use during cesarean delivery.
  
  
  BACKGROUND
  CTRI/2009/091/000075.
authors.affiliation: Department of Obstetrics and Gynecology, Chittaranjan Sevasadan College of Obstetrics, Gynecology and Child Health, Kolkata, Westbengal, India. picklu.chaudhuri@gmail.com
authors.forename: Picklu
authors.initials: P
authors.lastname: Chaudhuri
authors.forename: Gita Basu
authors.initials: GB
authors.lastname: Banerjee
authors.forename: Apurba
authors.initials: A
authors.lastname: Mandal
mesh_terms: D000285:Administration, Rectal; D000328:Adult; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002585:Cesarean Section / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D010121:Oxytocin / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011446:Prospective Studies; D014593:Uterine Inertia / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin